Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc.
Merck Sharp & Dohme LLC
Aulos Bioscience, Inc.
AstraZeneca
Neonc Technologies, Inc.
Replimune Inc.
TuHURA Biosciences, Inc.
Memgen, Inc.
Medicenna Therapeutics, Inc.
Marengo Therapeutics, Inc.